GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Voyageur Pharmaceuticals VM.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.14

+12.50%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

C$11,685

FY2016FY2025

Net income

−C$3.5m

FY2016FY2025

Free cash flow

−C$2.9m

FY2016FY2025

Shareholders' equity

C$1.3m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueC$11,685—————————
Gross profit——−C$2,185−C$2,908−C$2,246−C$1,483−C$2,120——−C$113,536
Research and developmentC$907,668C$287,439C$280,944C$527,561C$496,514—————
Operating income−C$3.5m−C$1.7m−C$1.3m−C$1.7m−C$2.1m−C$848,939−C$554,893−C$866,028−C$615,363−C$52,323
Net income−C$3.5m−C$1.7m−C$1.4m−C$1.8m−C$2.1m−C$1.1m−C$552,293−C$555,860−C$670,752−C$52,323
Diluted earnings per share-0.03-0.01-0.01-0.02-0.02-0.02-0.01-0.01-0.02-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$3.1mC$2.6mC$2.2mC$2.1mC$2.6mC$1.3mC$1.6mC$1.3mC$869,884C$709,319
Cash and short-term investments——C$2,085C$31,561C$812,967C$2,967C$75,613C$146,916C$17,048C$696,993
Total liabilitiesC$1.9mC$2.1mC$727,877C$630,826C$660,637C$968,845C$852,691C$750,787C$959,121C$38,861
DebtC$40,000C$40,000C$40,000C$25,520C$42,077C$268,408C$138,629C$179,648C$49,872—
Shareholders' equityC$1.3mC$449,958C$1.4mC$1.5mC$1.9mC$306,335C$754,090C$515,681−C$89,237C$670,458
Shares outstanding139m139m133m115m102m71m58m48m36m30m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$2.9m−C$302,289−C$991,252−C$1.7m−C$1.7m−C$272,194−C$637,807−C$490,452−C$624,237−C$35,070
Capital spending——−C$174,721−C$282,913−C$432,077−C$161,935−C$1,829−C$320,998−C$532,980−C$163,652
Free cash flow−C$2.9m−C$302,289−C$1.2m−C$2.0m−C$2.1m−C$434,129−C$639,636−C$811,450−C$1.2m−C$198,722

Latest quarters

By quarter end

May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
RevenueC$16,280C$19,274C$645C$11,000————
Gross profit——C$2,830−C$2,800————
Operating income−C$996,986−C$627,423−C$865,945−C$1.3m−C$544,257−C$817,559−C$450,572−C$359,130
Net income−C$996,986−C$627,423−C$865,946−C$1.3m−C$544,257−C$817,559−C$458,512−C$359,130
Diluted earnings per share-0.01-0.00-0.01-0.01-0.00-0.01-0.00-0.00
Cash from operations———−C$1.0m—−C$1.0m——
Total assetsC$3.2mC$2.9mC$3.1mC$3.7mC$3.0mC$3.2mC$2.6mC$2.3m
Cash and short-term investments———C$943,200————
Debt——C$40,000C$40,000C$40,000C$40,000C$40,000C$40,000
Shareholders' equityC$408,205C$660,738C$1.3mC$1.4mC$913,664C$1.2mC$449,958C$944,818

Growth per year

Compound annual rate

3 years5 years10 years
Operating income26.4%33.0%117.6%
Net income26.3%25.4%117.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-6.7-6.9-7.1-5.6-4.5-4.3-8.3-6.0-5.4-56.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-to-1 reverse split · 7 Mar 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.